Literature DB >> 16150831

Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes.

G Pütz1, W Schmider, R Nitschke, G Kurz, H E Blum.   

Abstract

To examine the possibility of targeting liposomes to hepatocytes via bile salts, the bile salt lithocholyltaurine was covalently linked to a phospholipid. The isomeric compounds disodium 3alpha-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy)ethoxy)-5beta-cholan-24-oyl-2'-aminoethansulfonate and disodium 3beta-(2-(1,2-O-distearoyl-sn-glycero-3-phospho-2'-ethanolamidosuccinyloxy)ethoxy-5beta-cholan-24-oyl-2'-aminoethansulfonate (DSPE-3beta-LCT) were synthesized and incorporated into liposomal membranes. Confocal laser scanning microscopy studies showed that bile salt-bearing liposomes (BSLs) attach to the surface of rat hepatocytes in culture. Studies with radioactively labeled liposomes revealed that the bile salt linked via the 3beta-conformation resulted in a higher attachment efficiency than that with the 3alpha-derivative. In the presence of BSLs corresponding to 2 mM liposomal phosphatidylcholine, uptake of 50 microM cholyltaurine (CT) into hepatocytes was reduced by approximately 40% by the 3beta-derivative and by approximately 17% by the 3alpha-derivative. When added simultaneously with the liposomes, CT up to 75 microM inhibited the binding of DSPE-3beta-LCT-bearing liposomes. By contrast, increasing concentrations reversed this inhibition and resulted in an increased bile salt-mediated binding. The same was true when CT was added 10 min before the liposomes were added. The attachment of BSLs to the surface of hepatocytes opens up promising possibilities for hepatocyte-specific drug delivery. More generally, not only substrates for cellular endocytosing receptors but also substrates for cellular carrier proteins should be suitable ligands for the cell-specific targeting of nanoscale particles such as liposomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150831     DOI: 10.1194/jlr.M500144-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  4 in total

1.  Two-Pronged Anti-Tumor Therapy by a New Polymer-Paclitaxel Conjugate Micelle with an Anti-Multidrug Resistance Effect.

Authors:  Juan Du; Lanlan Zong; Mengmeng Li; Keke Yu; Yonghui Qiao; Qi Yuan; Xiaohui Pu
Journal:  Int J Nanomedicine       Date:  2022-03-22

2.  Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Vinod C Malshe; Vaishali Pujari; Ajit Gorakshakar; Manisha Madkaikar; Kanjaksha Ghosh; Padma V Devarajan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Pitavastatin-loaded bilosomes for oral treatment of hepatocellular carcinoma: a repurposing approach.

Authors:  Maged Kharouba; Amal El-Kamel; Radwa Mehanna; Eman Thabet; Lamia Heikal
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 4.  Efficient hepatic delivery of drugs: novel strategies and their significance.

Authors:  Nidhi Mishra; Narayan Prasad Yadav; Vineet Kumar Rai; Priyam Sinha; Kuldeep Singh Yadav; Sanyog Jain; Sumit Arora
Journal:  Biomed Res Int       Date:  2013-10-28       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.